tiprankstipranks
Trevi Therapeutics 17.4M share Secondary priced at $5.75
PremiumThe FlyTrevi Therapeutics 17.4M share Secondary priced at $5.75
1M ago
Promising Phase 2b Results for Haduvio in IPF-CC Drive Buy Rating and Highlight Market Potential
Premium
Ratings
Promising Phase 2b Results for Haduvio in IPF-CC Drive Buy Rating and Highlight Market Potential
1M ago
Buy Rating for Trevi Therapeutics: Promising Phase 2b Results for Haduvio in IPF-CC
Premium
Ratings
Buy Rating for Trevi Therapeutics: Promising Phase 2b Results for Haduvio in IPF-CC
1M ago
Buy Rating for Trevi Therapeutics Driven by Promising Haduvio Trial Results and Market Opportunities
PremiumRatingsBuy Rating for Trevi Therapeutics Driven by Promising Haduvio Trial Results and Market Opportunities
1M ago
Trevi Therapeutics Reports Positive Phase 2b Trial Results
Premium
Company Announcements
Trevi Therapeutics Reports Positive Phase 2b Trial Results
1M ago
Trevi Therapeutics says ‘positive’ results from Phase 2b CORAL trial of Haduvio
Premium
The Fly
Trevi Therapeutics says ‘positive’ results from Phase 2b CORAL trial of Haduvio
1M ago
Trevi Therapeutics provides additional analysis of Haduvio in chronic cough
PremiumThe FlyTrevi Therapeutics provides additional analysis of Haduvio in chronic cough
2M ago
Buy Rating for Trevi Therapeutics Driven by Promising Haduvio Trial Results and Strong Efficacy in RCC and IPF Cough
Premium
Ratings
Buy Rating for Trevi Therapeutics Driven by Promising Haduvio Trial Results and Strong Efficacy in RCC and IPF Cough
2M ago
Trevi Therapeutics’ Haduvio Phase 2b CORAL Study: A Potential Milestone in IPF Cough Treatment
Premium
Ratings
Trevi Therapeutics’ Haduvio Phase 2b CORAL Study: A Potential Milestone in IPF Cough Treatment
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100